BioSpace News Archive

Acadia Pharmaceuticals Inc. announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.

Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time).

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Bristol Myers Squibb announced that the European Commission has expanded approval of Reblozyl® to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes.

Upstream Bio, a clinical-stage biotech company advancing verekitug for respiratory disorders, announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.